• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices

    Simply Stimulating: Examining the Neurostimulation Sector

    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Tracey Technologies Upgrades iTrace Software

    Foster Corporation Rebrands its Distribution Business

    Greenleaf Health Recruits Two Former FDA Officials

    TOTAL Toric Contact Lenses for Astigmatism Debuts in Canada

    FDA Approves Abbott's Epic Max Tissue Valve for Aortic Valve Disease
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices

    Simply Stimulating: Examining the Neurostimulation Sector

    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Timeline Mystery for Updated EtO Rules

    An Update on Hospital Trends Post-Pandemic

    Don’t Fear the Audit: Benefits of Good Quality Practices

    Understanding the FDA’s Standards & Conformity Assessment Program

    Medtech Divestitures Are Good for Medtech Innovation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    JBC Technologies

    Arthur G. Russell Co. Inc., The

    Providence Enterprise USA Inc.

    Fusion Biotec Inc.

    Halkey-Roberts Corporation
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Designing for Manufacturing: 5 Common Startup Mistakes (and How to Avoid Them)

    5 Challenges Medtech Must Address to Transform Healthcare

    3D Printing Medical Devices Revolutionized Manufacturing

    5 Current Trends in Medical Device Security

    How Advanced Sensors Improve Design & Functionality of Respiratory Care Equipment
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    JBC Technologies

    Arthur G. Russell Co. Inc., The

    Providence Enterprise USA Inc.

    Fusion Biotec Inc.

    Halkey-Roberts Corporation
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Today’s Regulatory Environment Challenges the Road to Innovation

    ...

    Today’s Regulatory Environment Challenges the Road to Innovation
    "Why be too disruptive if the FDA has no incentive to approve cutting-edge technologies?" —Dana A. Oliver
    Sean Fenske, Editor04.06.16
    Many involved with innovation and development in the medtech space face a number of challenges that impede their abilities to bring new medtech to market in a timely manner. There are a number of reasons for this including regulatory oversight, risk aversion, and business planning by the larger companies more focused on shareholders. While there are a number of industry leaders who privately share these opinions, there are few willing to speak as frankly about them as the person who spoke with MPO for this interview.

    Dana A. Oliver is the senior director of research and development at Medtronic’s Surgical Technologies ENT/NT division. He’s recently released his second book titled, “Mantra Design—Innovate, Buy or Die!” which is a follow-up to his first book, “Mantra Leadership—Don’t Become the Emperor with No Clothes!” Oliver has very distinct opinions on what challenges stand in the way of real innovation in medtech and what changes need to happen to eliminate them. In the following interview, he speaks of his new book, how the FDA is adversely impacting innovation, and how companies


    Dana A. Oliver is the senior director of research and development at Medtronic’s Surgical Technologies ENT/NT division.
     can remain innovative despite the obstacles in their way.
     
    Sean Fenske: There are quite a few who are calling for innovation in the medical device space. What does innovation mean to you?
    Dana A. Oliver: First let me explain that ideation is the creation of ideas, whereas innovation is the distillation to practice of those ideas and includes the advancement of technology—in this case, medical technology. If your company is dedicated to growth, innovation is readily available, but the average sizable medical device company is, frankly, a value company and is more interested in meeting their quarterly earnings. This means that these sizeable players are more interested in acquiring new technologies than developing them because an acquisition on the P&L, if accretive, looks more attractive than investing in local research and development. The irony is that the average start-up or growth medical company chose to pursue technology ideas that were born out of the more established medical institutions who were not committed to investing in them in the first place.
     

     
    Fenske: Speaking of innovation, you recently put out your second book. Can you please tell me what “Mantra Design” is?
    Oliver: Mantra Design is a collection of my innovation philosophies and best practices that reveals to innovation leaders how to identify your customer’s unmet needs and how to develop them into patent-protected, premium-priced, market-share leading products. Think of it as a self-help business innovation how-to book.
     
    Fenske: How does the subject relate to the medical device industry?
    Oliver: I have spent the last 30 years of my career in research and development in the medical device space and the book shares my philosophies that I have evolved and culminated in its writing over these past three decades. These same practices helped grow Surgical Technologies from $100 million to approximately $2 billion in a period of 14 years. With that said, these practices are not specific to medical devices, but are relevant to any company’s innovation process due to their focus on growth and customers.
     
    Fenske: In an industry such as medtech where an innovative product can take years before it hits the market, how does a company stay innovative?
    Oliver: One of the mantras I naturally embrace and share is the “Spend 15 percent of Your Time on Innovation!” rule. In short, this means at any given time, my R&D team as a whole is spending 15 percent of their time on next generation ideation and distillation to practice of next generation technologies. This ratio also means that 85 percent of my team is focused on advancing the core products and technologies in support of annual revenue growth that need to move the annual operating plan needle.

    Another benefit to the 15 percent contingency pool is that it ensures I always have a full pipeline of next generation technology waiting in the wings. I can momentarily tap this team if one of my active programs runs into trouble, but this 15 percent slice of their time is to focus on keeping the pipeline full.
     
    Fenske: Does the FDA and its procedures stifle innovation or is it a scapegoat/excuse for companies who aren’t innovative?
    Oliver: Without question, FDA is retarding medical device advancement. My words, of course, and not Medtronic’s opinion, but FDA has positioned itself to be adversaries of business and they regularly act like bullies. Their perspective is not reasoned and it clearly retards the advancement of medical devices and medical therapies. Further, it’s costing tax payers billions of dollars because their demand on compliance issues, which is not making products safer or more efficacious, is requiring medical device companies to hire multitudes of employees to work in areas such as Compliance Auditing, CAPA, and Complaints, in addition to the adoption of expensive electronic systems to harbor the vast information demanded, along with attempts to ensure electronic signatures are validated. These many hires and systems put in place help prevent a missing signature and minimize pagination errors, but they are doing little to prevent misbranding and product alteration. The reality is that these demands and expectations are increasing business overhead that is simply passed along to tax payers through government reimbursement. If FDA were true business partners and were reasonable and listened, the country would be better off. My team regularly jokes that we are developing Design History Files and not products. Instead of focusing on the product design and its safety, we are spending a disproportionate time focusing on ensuring check marks are in place to satisfy internal and government audits.
     
    Fenske: What’s your opinion on the innovation that’s happening outside the walls of the traditional medtech companies, such as at Google, Apple, and IBM?
    Oliver: Competition is good for innovation; look at the innovation that followed the breakup of AT&T’s monopoly—the by-product is the Apple I-phone and the rest is history. I do think this is good for innovation and I’m hoping it shakes up the medical device industry titans. The medical device industry is operating under an innovation philosophy that I call, “safe research.” This is favorable incremental and predictable advancement of technology and it’s not too extreme for the FDA to accept. This is also another example of how medical technology is moving slower than it could otherwise.
     
    Fenske: Does the medical device industry need to change the way it thinks about innovation in order to truly become innovative?
    Oliver: There are two major impediments to the industry, which in my opinion, limit innovation. The first is that the major medical companies are thinking short term to satisfy Wall Street’s earnings expectations. Second, why be too disruptive if the FDA has no incentive to approve cutting-edge technologies. Think about the traditional pharmaceutical clinical trial approach to bring forth a cure for Ebola versus what took place during the last outbreak in the US. The FDA has no incentives to take risks unless the public pressures it to do so; it’s safe to say no.
     
    Fenske: Much innovation happens at the small, start-up company level, which is then acquired by a larger medical device OEM. Is this a good innovation strategy for the larger OEMs?
    Oliver: I personally don’t prescribe to the “acquire and milk” strategy employed at the average medical device company. Innovation happens at small companies because they are focused on growth and satisfying unmet needs. The problem is that following acquisition by larger companies, they fall into the large institutional philosophy that limits the investments needed to keep growing them at an accelerated pace. Further, more than 50 percent of all acquisitions fail to give back value. I do support tuck-in acquisitions to augment a company’s portfolio, but I do not embrace the larger ones.

    I have another mantra: “Dance with the Girl You Came With!” This means to stay true and continue to invest in the technologies that made the company great in the first place. Companies can continue to grow if they are dedicated to investments in R&D at 10 percent or greater of their revenues and if they continue to evolve their core brands through their customer’s eyes.
     
    Fenske: Are changes needed within the medtech industry before we see a significant increase in the pace of innovation?
    Oliver: Innovation is retarded by the largest medical device institutions because they prescribe to being value companies and not growth companies. Further, the FDA is risk adverse and not truly interested in disruptive technologies. I’ll repeat myself, quarterly earnings myopia hurts true cutting-edge research and for the FDA, it’s safe to say no.
     
    Fenske: What do you think the impact of the device tax suspension will be on innovation?
    Oliver: Medical device companies sadly have already restructured to accommodate paying the taxes and this resulted by lessened research and development budgets, employee reductions, and deferred infrastructure investments. Now that this has already occurred, companies will reevaluate how best to position those monies, but my guess is that a significant percentage will be moved to make the companies more financially attractive while a lesser percentage will be reinvested back into research and development.
     
    Fenske: What’s ahead for innovation in the medtech space in five years? Ten years?
    Oliver: There are many interesting areas to watch—additive manufacturing or 3D printing, wearables, consumables, and stem cell research. Let me say there is not a lack of innovation going on; it’s a lack of funding and speed to market. Advancing technologies outside of medical, such as smaller, faster, and more flexible electronics and additive manufacturing, will be adopted and introduced into medical devices. Envision an artificial joint from a custom-printed technology or clothes that sense when someone suddenly falls or their blood pressure rapidly changes, signaling a heart attack or stroke, that automatically has your connected phone call 911. Think about swallowing a pill that monitors the body’s function and gives a report out a week later. Or one of my personal biggest frustrations is that people are dying while waiting for an artificial organ transplant, but what if someone could supply a sampling of their own DNA and have a laboratory grow a replacement organ. These opportunities in my eyes are very probable.
     
    Fenske: Before closing, do you have any other thoughts or comments you’d like to share?
    Oliver: I would hope that the FDA gets new leadership interested in partnering with medical device and pharmaceutical companies for the advancement of medicine and betterment of the general public. The agency’s existing tactics are more wasteful than good or helpful. Further, I would like to see medical device CEOs have a significant portion of their pay and equity determined by long-term business health (three to five years out), which would drive improved fiduciary responsibility. CEOs are too focused on rewarding shareholders instead of stakeholders. These two changes would better business and society as a whole.
    Related Searches
    • medical device companies
    • Medical Devices
    • stroke
    • wearables
    Related Knowledge Center
    • Contract Manufacturing
    • R&D & Design
    Suggested For You
    MEDICAL & BIOTECH MANUFACTURING MEDICAL & BIOTECH MANUFACTURING
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    Accu-Tube Appoints Matthew Haddle as CEO Accu-Tube Appoints Matthew Haddle as CEO
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    CE Mark Granted to Predictive Software for Kidney Allograft Survival CE Mark Granted to Predictive Software for Kidney Allograft Survival
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Precision Coating Merges with N2 Biomedical Precision Coating Merges with N2 Biomedical
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    RapidPulse Closes $15 Million Series A Financing RapidPulse Closes $15 Million Series A Financing
    Midwest Products & Engineering Acquires MindFlow Design Midwest Products & Engineering Acquires MindFlow Design
    Vicarious Surgical Opens New Corporate Headquarters in Massachusetts Vicarious Surgical Opens New Corporate Headquarters in Massachusetts
    Luis J. Malavé Joins Integrity Applications Board Luis J. Malavé Joins Integrity Applications Board

    Related Literature / Brochures

    • MEDICAL & BIOTECH MANUFACTURING

      ISO 13485:2016 • FDA Registered

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21

    • Tubing & Extrusion
      Accu-Tube Appoints Matthew Haddle as CEO

      Accu-Tube Appoints Matthew Haddle as CEO

      Haddle has a track record of leading organizations through strategic expansions across the medical device, aerospace, and industrial sectors.
      Accu-Tube 09.22.21


    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21

    • CE Mark Granted to Predictive Software for Kidney Allograft Survival

      CE Mark Granted to Predictive Software for Kidney Allograft Survival

      Algorithm gives the probability the graft will still be functional at three, five, and seven years after evaluation by a healthcare professional.
      Cibiltech 09.21.21

    Loading, Please Wait..

    Trending
    • Medinbox And Abbott Partner To Increase Efficiency In Electrophysiology Labs
    • FDA Clears LiveMetric's Wearable Blood Pressure Monitoring Tech
    • FDA Approves Abbott's Epic Max Tissue Valve For Aortic Valve Disease
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • A New Approach To Post-Market Surveillance
    Breaking News
    • Tracey Technologies Upgrades iTrace Software
    • Foster Corporation Rebrands its Distribution Business
    • Greenleaf Health Recruits Two Former FDA Officials
    • TOTAL Toric Contact Lenses for Astigmatism Debuts in Canada
    • FDA Approves Abbott's Epic Max Tissue Valve for Aortic Valve Disease
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Sensing Technology Drives the Future of Medical Care
    • New and Developing Diabetes Technologies Offer 'Sweet Relief'
    • Discussing Matters of Substance in Medtech Materials
    • Medical Device Testers Are Caught Up in a Whirlwind
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Jiaherb Receives CITES Certification for Rhodiola Rosea
    Hyaluronic Acid Ingredient Linked to Antioxidant Benefits In Vitro
    Anita Johansen Appointed New CEO of Probi
    Coatings World

    Latest Breaking News From Coatings World

    BASF’s Monomers Division Receive ISCC+ Certification in Its Two Asian Production Sites
    Omya to Represent Songwon’s Coatings Portfolio in 4 South-Asian Countries
    Brenntag Commences Operations at Its New Site in Zhangjiagang, China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Tracey Technologies Upgrades iTrace Software
    Foster Corporation Rebrands its Distribution Business
    Greenleaf Health Recruits Two Former FDA Officials
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Quotient Sciences Supports Crinetics Pharma with Pediatric Development, Clinical Testing Program
    Syndax Pharmaceuticals Names Neil Gallagher President, Head of R&D
    ABL Names Stephanie Colloud GM and COO in Europe
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arbonne Names New Chief Growth & Innovation Officer
    MAC Revamps 'Back To MAC' Recycling Program
    Coty Names New Chief Commercial Officer for Prestige Division
    Happi

    Latest Breaking News From Happi

    Maya Jama Named Rimmel London’s New Global Brand Ambassador
    Former Bliss Products CEO Meri Baregamian Named CEO of Give Back Beauty’s Indie & Talents Division
    Registration Now Open for Cosmoprof North America’s 20th Edition
    Ink World

    Latest Breaking News From Ink World

    ACTEGA to Showcase Products and Solutions at Interpack 2023
    hubergroup Print Solutions Takes Stock of Digital Print Folders
    INX International Makes Investment in Gooten
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Two from Sun Chemical honored with NAPIM Pioneer Awards
    Loftware secures significant growth equity investment
    Avery Dennison’s atma.io adds new ChatGPT and AI features
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Drylock Technologies Plants First Trees in Drylock Forest
    A.Celli Group to Hold Open House
    Toray Awarded for Nanodesign Technology
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Report: No Complications With OssDsign Catalyst Graft
    FDA OKs Bioretec's RemeOs Bioresorbable Metal Trauma Screw
    First Clinical Use of Stryker’s Tornier Pyrocarbon Humeral Head
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Emerson Named 2023 ENERGY STAR Partner of the Year
    Nano Dimension Increases Offer to Acquire Stratasys to $19.55 Per Share in Cash
    Universal Display Sponsors, Presents at ICDT 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login